Biotechnology - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

1 to 25 of 95 results

Doomed future for Tykerb in breast cancer arena, says analyst

Doomed future for Tykerb in breast cancer arena, says analyst

16-06-2014

The future of Tykerb (lapatinib) in the breast cancer market looks bleak, after the combination of GlaxoSmithKline’s…

BiotechnologyGlaxoSmithKlineMarkets & MarketingNovartisOncologyResearchTykerb

AFFiRiS reports breakthrough in Alzheimer's disease with AD04

AFFiRiS reports breakthrough in Alzheimer's disease with AD04

05-06-2014

Austrian biotech firm AFFiRiS has released Phase II results with its proprietary AD04 vaccine, saying…

AD04AFFiRiSBiotechnologyGlaxoSmithKlineNeurologicalResearch

GlaxoSmithKline surprises with mega-dollar deal for cancer program

GlaxoSmithKline surprises with mega-dollar deal for cancer program

02-06-2014

UK biotech firm Adaptimmune revealed this morning that it has entered into a collaboration and licensing…

AdaptimmuneBiotechnologyGlaxoSmithKlineLicensingOncologyResearch

ASCO 2014: latest news on lapatinib and trastuzumab, and ibrutinib

ASCO 2014: latest news on lapatinib and trastuzumab, and ibrutinib

01-06-2014

There was more important news on investigational oncology products presented at the 2014 Annual Meeting…

BiotechnologyGlaxoSmithKlineibrutinibJanssen BiotechJohnson & JohnsonLapatinibOncologyPharmacyclicsResearchtrastuzumab

BioVersys links with GSK and others to develop preclinical candidates in tuberculosis

27-05-2014

Privately-held Swiss biotech company BioVersys has entered a collaboration with UK pharma giant GlaxoSmithKline…

Antibiotics and Infectious diseasesBiotechnologyBioVersysGlaxoSmithKlineResearchWELLCOME TRUST

Epizyme earns $4 million milestone under GSK collaboration

22-04-2014

US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…

BiotechnologyEpizymeFinancialGlaxoSmithKlineLicensingOncology

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

Novel collaboration to use genomics and big data to drive drug discovery

27-03-2014

A pioneering public-private research initiative between UK pharma giant GlaxoSmithKline, the European…

BiotechnologyEuropeGlaxoSmithKlineResearch

Promising mid-stage results for Prosensa’s drisapersen in DMD boys

19-03-2014

Shares of Dutch biotech firm Prosensa Holding rose 3.85% to $7.02 after the firm reported encouraging…

BiotechnologydrisapersenGlaxoSmithKlineProsensaRare diseasesResearch

Amarin calls on FDA to extend Vascepa exclusivity by five years

28-02-2014

US biotech firm Amarin has filed with a federal court requesting it to order the US Food and Drug Administration…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLegalLovazaNorth AmericaUSAVascepa

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa

13-01-2014

UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Sarepta plunges as FDA questions eteplirsen trial results

Sarepta plunges as FDA questions eteplirsen trial results

12-11-2013

Shares of US RNA-based drug developer Sarepta Therapeutics plummeted in pre-market trading on November…

BiotechnologydrisaperseneteplirsenGlaxoSmithKlineNorth AmericaRare diseasesRegulationResearchSarepta Therapeutics

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

GSK and Genmab file for Arzerra variation in Europe

04-10-2013

GlaxoSmithKline ) and partner Genmab have submitted a variation to the Marketing Authorization to the…

ArzerraBiotechnologyEuropeGenmabGlaxoSmithKlineOncologyPharmaceuticalRegulation

Positive developments for GSK's Tafinlar/Mekinist and Arzerra

16-09-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) has announced positive news relating to three of its drugs,…

ArzerraBiotechnologyGenmabGlaxoSmithKlineMekinistNorth AmericaOncologyPharmaceuticalRegulationTafinlar

GlaxoSmithKline's cancer drug candidate fails endpoint in melanoma

05-09-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and partner US biotech firm Agenus (Nasdaq: AGEN) this morning…

AgenusBiotechnologyGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearchVaccines

GSK launches $50 million VC fund to invest in pioneering bioelectronic medicines and technologies

08-08-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) today (August 8) announced the launch of Action Potential…

BiotechnologyFinancialGlaxoSmithKlinePharmaceuticalResearchSetPoint Medical

US Court denies re-hearing of Arzerra patent case

16-07-2013

Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

GlaxoSmithKline and Theravance withdraw Japan NDA for Relvar Ellipta in COPD

12-07-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) revealed on Friday…

Asia-PacificBiotechnologyGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

GlaxoSmithKline files sNDAs for combination melanoma drugs

09-07-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) said today (July 9) that it has submitted supplemental New…

BiotechnologyGlaxoSmithKlineMekinistNorth AmericaOncologyPharmaceuticalRegulationTafinlar

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

1 to 25 of 95 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top